TIL vs. ELUT, TSBX, DTIL, GNTA, GRTS, IKNA, ENTX, ALGS, PASG, and JATT
Should you be buying Instil Bio stock or one of its competitors? The main competitors of Instil Bio include Elutia (ELUT), Turnstone Biologics (TSBX), Precision BioSciences (DTIL), Genenta Science (GNTA), Gritstone bio (GRTS), Ikena Oncology (IKNA), Entera Bio (ENTX), Aligos Therapeutics (ALGS), Passage Bio (PASG), and JATT Acquisition (JATT). These companies are all part of the "biological products, except diagnostic" industry.
Instil Bio (NASDAQ:TIL) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and profitability.
60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 74.0% of Elutia shares are owned by institutional investors. 54.7% of Instil Bio shares are owned by insiders. Comparatively, 37.1% of Elutia shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Instil Bio received 88 more outperform votes than Elutia when rated by MarketBeat users. However, 100.00% of users gave Elutia an outperform vote while only 51.98% of users gave Instil Bio an outperform vote.
Instil Bio has a net margin of 0.00% compared to Elutia's net margin of -106.54%. Elutia's return on equity of 0.00% beat Instil Bio's return on equity.
In the previous week, Instil Bio and Instil Bio both had 1 articles in the media. Elutia's average media sentiment score of 0.00 beat Instil Bio's score of -0.59 indicating that Elutia is being referred to more favorably in the news media.
Instil Bio has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, Elutia has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500.
Elutia has higher revenue and earnings than Instil Bio. Elutia is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.
Instil Bio presently has a consensus target price of $36.00, suggesting a potential upside of 239.62%. Elutia has a consensus target price of $6.00, suggesting a potential upside of 107.61%. Given Instil Bio's higher possible upside, research analysts plainly believe Instil Bio is more favorable than Elutia.
Summary
Elutia beats Instil Bio on 8 of the 15 factors compared between the two stocks.
Get Instil Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TIL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Instil Bio Competitors List
Related Companies and Tools
